Receiver operating characteristic (ROC) curves are widely used to measure the discriminating power of medical tests and other classification procedures. In many practical applications, the performance of these procedures can depend on covariates such as age, naturally leading to a collection of curves associated with different covariate levels. This paper develops a Bayesian heteroscedastic semiparametric regression model and applies it to the estimation of covariate-dependent ROC curves. More specifically, our approach uses Gaussian process priors to model the conditional mean and conditional variance of the biomarker of interest for each of the populations under study. The model is illustrated through an application to the evaluation of prostate-specific antigen for the diagnosis of prostate cancer, which contrasts the performance of our model against alternative models.
INTRODUCTION
Receiver operating characteristic (ROC) curves are widely used to evaluate the performance of diagnostic and prognostic biomarkers. For example, consider a diagnostic test based on a continuous marker, whose objective is to separate diseased from healthy individuals. Let Y be the value of the marker, which is assumed to be a continuous random variable with distribution F H in the healthy population and F D in the diseased population. Without loss of generality, we assume that the biomarker tends to be elevated in the diseased population so that, for a given threshold t, the event Y > t corresponds to a "disease" diagnosis, while Y t corresponds to a "healthy" diagnosis. Each value of the threshold t defines a different test based on this particular biomarker; lower values of t lead to low false-negative rates but high false-positive rates, while high values of t lead to high false-negative rates but low false-positive rates.
The ROC curve summarizes the tradeoffs between true and false positives associated with all possible tests obtained by changing the classification threshold t. More formally, the ROC curve is defined by the set of points {(FPR(t), TPR(t)) : t ∈ (−∞, ∞)}, where the false-positive rate is given by FPR(t) = 1 − F H (t) =F H (t), while the true-positive rate is TPR(t) = 1 − F D (t) =F D (t). Alternatively, the ROC curve can be expressed as
H (u)), 0 u 1.
(1.1)
Bayesian semiparametric estimation of covariate-dependent ROC curves
355 parameter υ i, j be independently distributed from a Gamma distribution with mean 1 and variance 2/ν i , υ i, j ∼ Gam(ν i /2, ν i /2), leads to errors that are (marginally) distributed as a Student's t distribution with ν i degrees of freedom (West, 1987) , i.e.
Note that, by treating the number of degrees of freedom ν i as an unknown parameter, this formulation allows us to learn about the weight of the tails of the error distribution and to be robust to the presence of outliers (West, 1984) .
For the observed sample, (2.1) becomes:
. . g i (x i,n i ))
T , and i is a diagonal matrix where [ i ] j j = exp{2g i (x i, j )}/υ i, j . Furthermore, the specification in (2.1) implies that, for any given x, the conditional distribution F i,x is simply a Gaussian with mean f i (x) and variance exp{2g i (x)}/υ i, j , or after integrating over υ i, j , a t distribution with location parameter f i (x), scale parameter exp{g i (x)}, and ν i degrees of freedom. Hence, the conditional ROC function reduces to 
Non-parametric regression through Gaussian process priors
A random function f : R q → R is said to follow a Gaussian process prior with mean function h : R q → R and covariance function γ :
Hence, γ (x, x ) controls a priori the variability of the realization f (x) around the centering function h(x). The choice of covariance function also controls the degree of smoothness in the realizations of process (Banerjee and Gelfand, 2002) . For example, realizations from a process with an exponential covariance function, κ 2 exp{−|x − x |/λ}, are nowhere mean-squared differentiable, whereas realizations from a process with a Guassian covariance function, κ 2 exp{−|x − x | 2 /λ}, are infinitely mean-squared differentiable everywhere.
Our model employs Gaussian process priors to create flexible models for the regression functions f D , f H , g D , and g H . More specifically, we let f i ∼ GP(h i,1 , γ i,1 ) and g i ∼ GP(h i,2 , γ i,2 ), which implies that
, where f i and g i were defined in Section 2 and h i,k
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A. RODRÍGUEZ AND J. MARTÍNEZ and i,k are defined as in (2.4). In the example we discuss in Section 4, the mean functions take the form
so that our heteroscedastic semiparametric regression model is centered a priori around a homoscedastic linear regression. Although other centering functions can be easily accommodated, this choice reflects our desire to center our non-parametric model around a simple parametric alternative that can be seen as representing standard practice.
On the other hand, in our illustration the covariance functions are assumed to be members of the anisotropic, separable exponential family
In this case, κ 2 i,k controls the total variability of the functions around their mean and λ i,k,l controls the dependence in the direction of covariate l. As discussed before, the choice of an exponential covariance function implies the assumption that the mean and log-standard deviation functions are nowhere mean-squared differentiable. Although this might seem an awkward choice, the use of covariance functions with low degrees of smoothness tends to lead to interpolators with lower mean-squared errors (e.g. see Stein, 1999, Chapter 3.5) . Furthermore, in addition to appealing theoretical properties, the use of exponential covariance functions alleviates computational instabilities associated with the inversion of covariance matrices computed from smoother covariance functions such as the Gaussian. On the other hand, the choice of an anisotropic structure for the covariance function allows the level of dependence to adjust to the scale associated with each covariate, but implies the assumption that the function is roughly equally smooth for all values of the covariates (an assumption that, we believe, is generally justifiable in this type of applications).
The model is completed by eliciting prior distributions on the hyperparameters of the model. For computational simplicity, we select independent, conditionally conjugate priors for {(μ i , θ i )} and {ω i }, so that
. On the other hand, for the covariance function, the range parameters are assigned Gamma priors λ i,k,l ∼ Gam(c i,k,l , d i,k,l ) while the variance parameters are assigned half normal priors with density
The use of a Gamma prior for κ 2 i,k (instead of the more common inverse-Gamma prior) simplifies hyperparameter elicitation without complicating computation. Indeed, note that this parameter is sampled as part of a Metropolis-Hastings step (see Section 3), so conditional conjugacy is not particularly critical in this case. Furthermore, one of the prior expectations required by our prior elicitation procedure (see Section 3.2, and in particular equation (3.6)) does not exist in the case of an inverse-Gamma prior, but it does exist in the case of a half normal prior. Finally, the number of degrees of freedom of the error distribution ν i is given a discrete uniform prior with support on {3, 4, . . . , 60}. For the sample sizes considered in our illustrations, larger values of the ν i lead to essentially equivalent behaviors in the relevant quantiles of the tail of the error distributions.
Summarizing the ROC curve
The discrimination power of ROC curves is typically summarized using the area under the curve (AUC). In the case of our covariate-dependent ROC curves, the conditional AUC, denoted by AUC x , is simply Bayesian semiparametric estimation of covariate-dependent ROC curves 357 defined as
(2.5) AUC x can be interpreted as the probability that an individual with associated covariate x randomly chosen from the diseased population exhibits a value for the biomarker that is larger than the one exhibited by a second individual with the same value of x but otherwise randomly selected from the healthy group. Larger values for the AUC x indicate a procedure with higher discriminating power at a given covariate level x. Indeed, a perfect biomarker at covariate level x would have AUC x = 1, while a biomarker with no discriminating ability at covariate level x would have AUC x = 0.5. An alternative measure of discriminating power is the partial AUC (pAUC) (Wieand and others, 1989; McClish, 1989) ,
Clearly, pAUC x (0, 1) = AUC x , while other combinations of a and b allow us to focus on particular regions of the ROC curve that might be relevant to the problem at hand. Although, to the best of our knowledge, no closed form solutions for (2.5) and (2.6) are available, both can be evaluated numerically using quadrature methods.
COMPUTATIONAL IMPLEMENTATION AND PRIOR ELICITATION
The posterior distribution associated with our model can be factorized as
Since (3.2) is not analytically tractable, we resort to MCMC algorithms (Robert and Casella, 2005 ) for posterior computation. Given an initial value
for the model parameters, our MCMC algorithm proceeds by iteratively updating blocks of parameters by sampling from the following set of full conditional distributions (further details on the algorithm are presented in Appendix B of supplementary material available at Biostatistics online):
, which is sampled using another random walk Metropolis-Hasting sampler; 7. p({υ i, j } | · · · ), which are conditionally independent and follow a Gamma distributions; 8. p(ν i |¨{υ i, j } · · · ), which is sampled from a discrete distribution.
This iterative procedure produces a dependent sample
which can be used to compute estimates of η x (u) or AUC x for any x and u through Monte Carlo integration. For example,
where
H (x)}. Credible intervals and other functionals of interest can be obtained in a similar way. For example, we might be interested in formally testing whether a given biomarker has a better discriminating power for individuals with covariate level x than for individuals with covariate level x . In a Bayesian setting, this can be done by computing
where I{A} denotes the indicator function on the set A and AUC
desired, these probabilities can be directly transformed into Bayes factors by noting that, under our model, Pr(AUC x > AUC x ) = 0.5 a priori for any pair x and x .
Interpolation
In addition to estimating the ROC curve and the AUC at observed covariate values, our model allows us to obtain estimates of these quantities at unobserved values of the covariates. Recall that, for any unobserved value
which implies that 
T . An analogous expression is available for the predictive of the log-standard deviation function,
as part of the MCMC scheme described above, which in turn can be used to obtain posterior samples for η x * (u) and AUC x * .
Hyperparameter elicitation
We use hyperparameters that are chosen to reflect the general location and scale of the data. We choose the hyper parameters for κ i,1 , ω i , and κ i,2 in tandem by setting ξ i , τ 2 i , b i,1 , and b i,2 so that, a priori,
where s 2 i is a rough estimate of total biomarker variability in population i, and ζ ∈ [0, 1] is a tuning parameter. The goal here is to approximately split the total observed variability in the biomarker for population i, so that a priori, roughly 100 × ζ % is associated with the variation in the underlying mean function while the remaining 100 × (1 − ζ )% is associated with the observational noise. If no strong prior information is available, we recommend selecting ζ = 0.5 as a default value and performing a sensitivity analysis that uses values of ζ in the interval [0.05, 0.5] (as we do in our illustration in Section 4). We recommend working with smaller values of ζ because we are interested in favoring models that are "close" to what could be considered the default model (a binormal model without covariates), which is obtained by letting ζ = 0, θ = 0, and ν = ∞. The value of s 2 i can be elicited either from expert information (e.g. the typically expected range of the biomarker in each population, which might have been inferred from previous studies) or, in the spirit of empirical Bayes approaches, selected from an in-sample estimate of biomarker variability (e.g. the sample range, max j n i {y i, j } − min j n i {y i, j }, or sample variance,
Note that (3.4) and (3.5) are not enough to fully specify all four model hyperparameters ξ i , τ 2 i , b i,1 , and b i,2 . Hence, we additionally consider the condition
where v 2 i is a rough estimate of the variance of the biomarker's variance. As before, v 2 i can either be elicited from expert information, or we can use a rough in-sample estimate obtained by binning the data and computing the variance of the empirical variances on each bin. Furthermore, in the spirit of unit information priors (Kass and Wasserman, 1995) , we set τ
. For the range parameters, we again set c i,k,l = 2 for all i ∈ {D, H }, k = 1, 2, and l = 1, . . . , q, and select
This choice implies that the correlation between two values of the function associated with covariates that lie in opposite extremes of the covariate space along the lth dimension is "small" a priori. Choosing the prior value for the range parameter of the covariance function in this way, and in particular using the value 0.05 to represent a "small" spatial correlation in the case of covariance function without a compact support, is customary in spatial statistics (e.g. see Banerjee and others, 2004) . In our experience, the results are not very sensitive to reasonable changes in the prior minimum value of the correlation among observations (say, in the range [0.01, 0.1]), but we recommend carrying out a sensitivity analysis (as we do in Section 4).
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−1 where X i is an n i × (q + 1) matrix whose first column is a vector of ones, its lth column corresponds to the vec-
T , for l = 2, . . . , q + 1, and ψ i is a tuning parameter which we set to ψ i ≈ E(exp{2ω i }).
Evaluating goodness of fit
To asses model fit, we focus on the posterior distribution of the standardized residuals,
Note that, under our model assumptions, these standardized residuals should be independently distributed according to a standard normal distribution. Hence, the transformed standardized residuals,
where denotes the cumulative distribution of the standard normal distribution, should be independently distributed according to a uniform distribution on the unit interval. Given a sample from the posterior distribution of model parameters, we can estimate the expected value and corresponding 95% pointwise credible intervals for the empirical distribution function of the transformed residuals z H, j and z D, j over a dense grid of points, and plot them against the cumulative distribution function of the uniform distribution. Interpretation of these plots is similar to the interpretation of standard quantile-quantile plots, with the added advantage that uncertainty in model parameters is accounted for.
THE EFFECT OF PATIENT AGE ON PSA AS A BIOMARKER FOR PROSTATE CANCER
Total PSA is a serological biomarker often used for the diagnosis of prostate cancer. Although it is normal for low levels of total PSA to be present in the blood of healthy males, prostate cancer (but also benign conditions such as prostatitis or benign prostatic hyperplasia) produces elevated levels of serological PSA.
In this section, we analyze a dataset introduced in Etzioni and others (1999) , which consists of total PSA levels for 454 healthy males and 229 males with prostate cancer. PSA levels in males tend to change with age for both healthy and diseased patients because, as men age, both benign prostate conditions and prostate cancer become more common. This pattern suggests that the discriminating ability of PSA might vary with the age of the subjects. The semiparametric regression model described in Section 2 was used to estimate the distribution of log PSA in both populations along with the resulting age-dependent ROC curves. The following results were obtained by taking ζ = 0.5. Posterior inferences are based on 100 000 samples of the MCMC algorithm described in Section 3, which were obtained after a burn-in period of 5000 iterations. Convergence was monitored by visual inspection of trace plots and by applying the multichain method described in Gelman and Rubin (1992) . These techniques were used to monitor the hyperparameters {λ i,k }, {κ 
while the shaded areas correspond to point estimates of 95% pointwise prediction intervals for log PSA levels,
overlaid on top of the raw data. As expected, our estimates capture the increase in average PSA level with age in both population, as well as the heteroscedasticity in the healthy group. For the healthy patients, the model also captures a slight acceleration in the rate of growth of average PSA levels for individuals around 65 years of age. Figures 2(a) -(e) present posterior means for the ROC curves at five selected ages, along with 95% pointwise credible intervals. To facilitate comparisons, Figure 2 (f) compiles these estimates into a single graph, and overlays a non-parametric estimate of the empirical ROC curve, which ignores the effects of age in the level of the biomarkers. As expected, the shape of the curve varies with the age of the patients. Also, note that greater uncertainty in the estimates of the ROC curve is present at low or high ages, where data are more sparse.
To quantify the differences in discriminating ability for PSA as age increases, Figure 3 (a) presents estimates of AUC x along with pointwise 95% credible intervals. Note that the AUC would seem to slightly increase between the ages of 50 and 55, to then steadily decline as age increases. To formally test for differences in discriminating power with age, we present in Figure 3 (b) the posterior probability that AUC x is greater than AUC 50 for various ages. Note that this graph provides weak to moderate evidence of an increase in discriminating power with age until patients reach 57 years of age (with a moderate evidence that AUC at age 57 is greater than at age 50), but then the discriminating power starts to decrease (again, with moderate evidence that AUC at age 75 is smaller than AUC at age 50).
To investigate the sensitivity of the model to prior specification, we also estimated the model assuming ζ = 0.1 and ζ = 0.25, as well as varying the prior mean of the range so that, a priori, the correlation among the PSA measurement for the youngest and oldest individuals in the sample decays to is 0.01 and 0.1. Although the posterior distributions of the hyperparameters differ somewhat from those obtained under ζ = 0.5, the estimates of the ROC curves and AUC are qualitatively unchanged. The only noteworthy difference arises in Figures 3(a) and (b), in which the initial increase in AUC is diminished and the later increase is slightly accentuated (resembling more the estimates obtained by the kernel smoothing method discussed in Section 4.1). Finally, Figure 4 presents the expected value and corresponding pointwise credible intervals for the empirical distribution function of the transformed standardized residuals discussed in Section 3.3. Note that in both cases the credible intervals contain the diagonal line (corresponding to the distribution function of the uniform distribution on the unit interval), suggesting an adequate fit of the model to the data.
Comparison against other models
To illustrate the advantages of our model for estimating covariate-dependent ROC curves in the context of the PSA data, we present in this section comparisons against two other models. First, we consider a parametric Bayesian model that assumes linearity in the mean and log-standard deviation functions, i.e. AUC as a function of age Probability that AUC improves with age 
We implement this parametric model because, as suggested by the reviewers, a cursory inspection of the raw data suggests that it can provide a reasonable fit. Both prior elicitation and computational implementation follow along similar lines to our semiparametric model. In particular, we use Gaussian priors for the regression coefficients associated with both the mean and log-variance functions, and parameters are estimated thorough an MCMC algorithm that involves the use of slice samplers for the coefficients of the log-standard deviation function.
Figures 5(a) and (b) present point estimates of the mean regression functions for both groups of males under this linear model, along with the associated pointwise prediction intervals. Note that the parametric linear model estimates of the variance of the distribution of total PSA concentration in the healthy group grows continuously over time. This is in contrast to the results generated by our model, which suggest that the variance stays roughly constant for males between 50 and 55 year, and for those between 60 and 65.
To formally compare the performance of our model against this parametric alternative, we computed the conditional predictive ordinate (CPO) (Geisser and Eddy, 1979) for each population i and observation j, defined as
for the linear and non-parametric models, respectively. Note that both sets of quantities can be readily computed from the MCMC samples using the harmonic mean of the likelihood of each observation over MCMC samples. Furthermore, the average of the logarithm of the CPOs, lCPO To further understand the tradeoffs associated with the use of non-parametric models in this context, consider also the estimates of the ROC curves presented in Figure 6 , as well as the estimate of the AUC as a function of time presented in Figure 6 (c). First, note that assuming a non-parametric structure for { f i } and {g i } does not lead to a substantial increase in the uncertainty associated with the estimates of the ROC curves (compare the graphs in Figure 6 with Figures 2(b) and (d) ). Furthermore, note that the model that assumes that both the mean and log-variance functions are linear leads to an estimate of the AUC function that decreases monotonically with age. In contrast, our non-parametric model leads to an estimate that is first increasing (roughly, until age 57), and then decreasing (recall Figure 3(a) ). This difference has important implications in the evaluation of PSA as a cancer biomarker, as the non-parametric models suggest that the age at which PSA becomes unreliable is higher than the age suggested by the linear model.
Our second comparison is against the non-parametric regression method discussed in Rodríguez-Álvarez, Roca-Pardiñas and others (2011), which uses kernel regression techniques to estimate the mean and variance functions, along with the empirical distribution function of the residuals. This method (for which, to the best of our knowledge, there is no publicly available software) was implemented by us using the R package np with the default choice of smoothing parameters. Figures 5(c) 
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A. RODRÍGUEZ AND J. MARTÍNEZ and (d) present point estimates of the mean regression function, as well as pointwise prediction intervals associated with each one of the two groups. Although the estimates generated by both non-parametric regression models are quite similar, we can see that the kernel-based estimates tend to be smoother than the ones generated by our model (most likely, a consequence of their use of Gaussian kernels for smoothing), and that estimates of the variance function in the diseased group tend to become somewhat unstable for older individuals. Additionally, Figure 6 (d) presents the estimate of the AUC as a function of time under the model introduced by Rodríguez-Álvarez, Roca-Pardiñas and others (2011) . Again, the inferences generated by this kernel-based method are very similar to the ones obtained under our model, but the uncertainty estimates seem to suffer from edge effects that do not appear in our model.
DISCUSSION
We have presented a semiparametric Bayesian approach to the estimation of covariate-dependent ROC curves. Our approach is semiparametric because even though it assumes a non-parametric model for the mean and variance functions associated with the distribution of the biomarker in the populations being compared, it assumes that the conditional error distribution is a Student's t (albeit, with an unknown number of degrees of freedom). This model provides an alternative to the one discussed in Inácio de Carvalho and others (2013) that focuses on directly modeling the mean and variance functions rather than the overall conditional distribution of the data. The approach discussed in this paper focuses on modeling the dependence of ROC curves with respect to continuous predictors. Mixed continuous and discrete predictors can be incorporated using hierarchical extensions of our model that involve functional ANOVAs, in the spirit of Kaufman and Sain (2010) . Another natural extension of our model involves the use of an additional level to the hierarchical specification of the model so that information can be borrowed between the healthy and diseased groups. However, we would expect this extension to have only a minor impact in the final results.
In the illustration discussed in the paper, we have focused on exponential covariance functions, mostly because of their numerical stability and good predictive properties. Extending the model to more general covariance functions such as the power exponential family is relatively straightforward. However, in small to moderate sample sizes such as the ones in our illustration, the advantages of using a more general covariance function are limited. Indeed, estimating parameters that control the smoothness of Gaussian processes is notoriously hard (e.g. see Palacios and Steel, 2006) .
One common concern with the application of non-parametric methods is the impact of sample sizes on performance. We further investigated this issue using a small simulation study, which is available as part of supplementary material available at Biostatistics online. The results from this simulation study, along with those presented in Section 4, suggest that using non-parametric methods does not necessarily lead to a substantial increase on posterior uncertainty when compared with parametric estimates, even in situations where the parametric model corresponds to the true data-generation mechanism. However, the results do suggest that, in that kind of situations, the performance of non-parametric models can suffer in regions of the covariate space where data are relatively sparser.
